New drug may cut transfusion needs for rare blood cancer patients
NCT ID NCT05732961
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called luspatercept in 6 adults with lower-risk myelodysplastic syndromes (MDS) or related blood cancers who have anemia. The goal is to see if the drug can reduce or eliminate the need for regular blood transfusions. Participants receive luspatercept plus standard care, and researchers monitor safety and how long any benefit lasts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug that boosts red blood cells help anemia in kidney disease?
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- A pill that mimics the body's oxygen sensor may free MDS patients from frequent blood transfusions
- Can a modified interferon rein in early myelofibrosis?
- Can pressurized oxygen boost cord blood transplants?
- Could a common heart drug help kids on dialysis fight anemia?